Cannabis Law Report

NOVEMBER 26, 2019

The FDA also published a revised Consumer Update detailing safety concerns about CBD products more broadly. This includes ongoing work to obtain and evaluate information to address outstanding questions related to the safety of CBD products, while maintaining the agency’s rigorous public health standards.

Safety 64

Safety Food CBD Oil 64

Cannabis Law Report

JANUARY 27, 2020

Those lessons include what’s been happening in states that have legalized marijuana – including various problems with everything from taxation and regulation to road safety – as well as input from state lawmakers and border states with New York that are eyeing marijuana legalization as well. Read the full report at [link].

Media 59

Media Programs Safety Treatment 59

Cannabis Law Report

JULY 28, 2021

InnarisBio), to develop a novel sol-gel intranasal drug delivery technology to improve treatments for mental health disorders. InnarisBio aims to be a revolutionary technology company for intranasal drug delivery in the treatment of CNS disorders. atai – Media Contact: Anne Donohoe. UniQuest – Media Contact: Brooke Baskin.

Research and Development 98

Research and Development Programs Treatment Media 98

MMJ Recs

MAY 29, 2024

For many patients, traditional treatment options may fall short of providing relief from debilitating symptoms. Patients must have a certification from a registered physician confirming their diagnosis and recommending medical marijuana as a treatment option. Image by Iñaki del Olmo on Unsplash. You can find an approved physician here.

Marijuana 52

Marijuana Programs Patients Conditions 52

Cannabis Law Report

DECEMBER 26, 2021

The patent relates to improved technology for detection and maintenance of the optimal therapeutic psychedelic state, which Entheon intends to study through the monitoring of electroencephalogram (EEG) biomarkers in order to optimize the treatment of neuropsychiatric conditions. US Provisional Patent Filed. About Entheon Biomedical Corp.

Research and Development 52

Research and Development Clinical Trials Treatment Packaging 52

Cannabis Law Report

OCTOBER 22, 2021

–The Company expects to hold a Research & Development event to review,these breakthrough findings in Q4 2021 that will be open to the public, shareholders, analysts and the media– TORONTO, CANADA – October 19, 2021 – Cybin Inc.

Research and Development 52

Research and Development Safety Media Data 52

MMJ Recs

OCTOBER 13, 2023

For patients seeking access to this valuable form of treatment, it’s essential to understand the complex web of regulations, legal requirements, and rights surrounding medical marijuana in the Golden State. California has long been a pioneer in the field of medical marijuana, and its MMJ laws have continued to evolve over the years.

Patients 52

Patients Law Cultivation Dispensary 52

Cannabis Law Report

JUNE 10, 2021

CURE has established itself as a leader in the oral application of cannabis-derived treatments, and we know we’ll be able to bring a lot of value to patients together.”. Media Contacts: Monica M. Jaramillo, mjaramillo@labeltheagency.com Kathryn Brown CMW Media, kathryn@cmwmedia.com. About CURE Pharmaceutical Holding Corp.

Pharmaceutical 75

Pharmaceutical DEA Research and Development THC 75

MMJ Recs

OCTOBER 5, 2023

With a growing number of MMJ dispensaries, a comprehensive set of laws, and a streamlined process for obtaining a medical marijuana card, the state has become a hub for patients seeking alternative treatments. These laws are designed to protect patients, provide access to treatment, and prevent abuse.

Dispensary 52

Dispensary Patients Treatment Conditions 52

Cannabis Law Report

OCTOBER 4, 2021

As a result, the TGA had not evaluated these products for quality, safety or efficacy and the manufacturer had not obtained relevant approvals. The TGA alleges that the individual also made a prohibited representation , on a related social media platform, in relation to the use of CBD oil for the treatment of cancer.

Law 52

Law Treatment Medicine CBD 52

CannaMD

MARCH 8, 2021

Prohibiting a medical marijuana treatment center from dispensing marijuana that exceeds a certain potency of tetrahydrocannabinol [p. Revising a provision relating to the potency of tetrahydrocannabinol in edibles dispensed by a medical marijuana treatment center [p.1, 2, line 32]. 2, line 38]. 1, line 12]. 2, line 26]. 2, line 29].

THC 116

THC Research and Development Treatment Patients 116

Cannabis Law Report

OCTOBER 6, 2021

Delic Labs is leading the way in psychedelic compound testing and ensuring the safety and effectiveness of any treatments produced using them, while also actively researching potential new medicines for the market.”. About DELIC Corp. The Canadian Securities Exchange ?has for the adequacy or accuracy of this release.?.

Research and Development 52

Research and Development Extraction Treatment Safety 52

Cannabis Law Report

MAY 6, 2022

The FDA explains it is monitoring the selling of CBD and Delta-8 THC products out of a growing safety concern. In short, the FDA has not evaluated or logged all dangerous side effects or safety concerns. Delta-8 is known to be successful in many cancer treatments.”.

THC 52

THC CBD Media Food 52

Cannabis Law Report

APRIL 13, 2022

Securing a Dealer’s License to accompany its existing research exemptions would cement Delic Labs’ position as the leader in psychedelic safety testing. The Company aims to establish consistent quality control standards as more patients and clinicians incorporate psychedelic compounds into treatment plans.

Research and Development 52

Research and Development Treatment Extraction Medicine 52

Canna Law Blog

APRIL 13, 2019

The letters were sent “in response to their making unsubstantiated claims related to more than a dozen different products and spanning multiple product webpages, online stores and social media websites.” Specifically, the agency fears that.

CBD 91

CBD Safety Topical Food 91

Project CBD

FEBRUARY 28, 2023

5 In June 2018, the FDA approved Epidiolex® (GW Pharmaceuticals; Cambridge, UK), the first FDA-approved pharmaceutical drug to contain a “purified drug substance [CBD] derived from marijuana,” for the treatment of seizures associated with two rare epilepsy disorders. Available at: www.fda.gov/media/131878/download. 2021.06.005.

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

DECEMBER 9, 2021

The study involved 100 treatment-resistant patients and were randomized to psilocybin or the nicotine patch, each receiving the same cognitive-behavioral therapy. At 12 months, 59% of the patients who received the psilocybin treatment remained abstinent, while only 28% of those who received the nicotine patch remained abstinent.

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

Cannabis Law Report

AUGUST 21, 2019

Cannabis treatments are too expensive and do not come with enough test evidence to be effective, UK authorities have said. It also said current treatments for adults suffering severe symptoms were “not cost effective”. This would answer questions about safety and efficacy, they said. AUTHOR: Mark Taylor.

Clinical Trials 81

Clinical Trials Nerve Pain Medicine Epilepsy 81

Cannabis Law Report

JANUARY 24, 2022

–(BUSINESS WIRE)–Goldfinch Bio, a clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced the appointment of Edwin (Ed) Tucker, M.D., Media: Liz Melone. CAMBRIDGE, Mass.–(BUSINESS Goldfinch Bio: Investors: Hannah Deresiewicz.

Clinical Trials 52

Clinical Trials Research and Development Data Medicine 52

The Blunt Truth

AUGUST 13, 2019

On May 31, 2019, the FDA’s Working Group held a public hearing for stakeholders to share their experiences and challenges with CBD products, including information and views related to product safety. The public hearing attracted over 100 speakers and 2000 participants. The FDA has historically been passive in its oversight of CBD products.

CBD 80

CBD Food Seed-To-Sale Wellness and Beauty 80

Veriheal

MARCH 1, 2022

The campaign manager of the ‘Yes on 109’ campaign that helped see the measure passed, Sam Chapman, told media sources, “There’s a huge breadth of expertise on this board from harm reduction experts to folks that have experience working with different populations that stand to benefit from having access to psilocybin therapy.

Therapy 98

Therapy Programs Microdosing Medicine 98

Cannabis Law Report

JULY 24, 2021

This expansive patent would allow Mydecine to scale its coverage in drug development research in lieu of promising discoveries and FDA-approval progress for novel therapeutics, including granting Breakthrough Therapy Designation to MDMA for the treatment of PTSD in recent years. For more information, please contact: Media Contacts.

Research and Development 105

Research and Development Clinical Trials Therapy Events 105

MMJ Recs

MARCH 2, 2024

Insider Tips for Ohio Medical Marijuana Dispensary Visits Join loyalty programs and follow dispensaries on social media platforms to access exclusive promotions and discounts. Observing discretion in discussions regarding medical conditions and treatment enhances privacy and respect among patrons.

Dispensary 52

Dispensary Patients Marijuana Education 52

Cannabis Law Report

AUGUST 12, 2021

Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021. Leadership hires in clinical science, regulatory affairs, clinical safety, quality and manufacturing, in preparation for phase III, new compounds and additional indications.

Clinical Trials 98

Clinical Trials Therapy Research and Development Data 98

Veriheal

OCTOBER 1, 2020

In 2018, the government was confronted by a media storm that has called for them to act. The media storm came about as 12-year-old Billy Caldwell and 6-year-old Alfie Dingley were being denied cannabis oil as a treatment for their epilepsy. As a result, the UK proposed medicinal cannabis regulations in 2018. .

Legalization 104

Legalization Oil Medicine Media 104

Cannabis Law Report

NOVEMBER 22, 2019

MMJ will be utilizing its new products for an FDA approved treatment of multiple sclerosis (MS) and Huntington’s disease (HD). for its THC and CBD proprietary drug formulation which will be used for the treatment of Huntington’s Disease. For media inquiries please contact: Michael Sharp. Orphan Drug Designation?

DEA 66

DEA Clinical Trials THC Research and Development 66

Cannabis Law Report

MAY 26, 2022

So we need to discuss openly and critically how we can remain balanced and ensure the potential of psychedelics can be optimised without compromising safety.”. And how do we make sure treatments are safe, accessible, and inclusive? Learn more about ICPR 2022 by connecting on social media using the #ICPR2022 hashtag.

Research and Development 52

Research and Development Therapy Policy Media 52

Canna Law Blog

APRIL 3, 2020

What we don’t need in this situation are companies preying on consumers by promoting products with fraudulent prevention and treatment claims. This is some of the language included with the products that the FDA deemed unlawful: Corona virus treatment. These warning letters are just the first step.

CBD 62

CBD Tincture Treatment Media 62

Cannabis Law Report

AUGUST 3, 2021

Cybin is a leading biotechnology company focused on progressing psychedelic therapeutics by utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. Cybin makes no medical, treatment or health benefit claims about Cybin’s proposed products.

Clinical Trials 105

Clinical Trials Events Treatment Banking 105

Veriheal

MAY 17, 2021

Theodore happens to also be an addiction expert who refuses to provide treatment to patients that choose to consume cannabis as he believes it interferes with the treatment of other addictions. She ends the column by stating “ I urge our legislators to abandon this legislation for the sake of our citizen’s health and safety.”.

Legalization 86

Legalization Pharmaceutical Therapy Chronic Pain 86

Cannabis Law Report

SEPTEMBER 15, 2021

This deceptive marketing of unproven treatments raises significant public health concerns because patients and other consumers may use them instead of approved therapies to treat serious and even fatal diseases. The FDA is aware of media reports of delta-8 THC products getting consumers “high.” brownies, gummies).

THC 105

THC Pets Events Hemp 105

MMJ Recs

FEBRUARY 29, 2024

In Florida, licensed Medical Marijuana Treatment Centers (MMTCs) are authorized to cultivate, process, and dispense medical marijuana to qualified patients. It empowers patients to take an active role in their treatment, providing a level of control over the cultivation process and the specific strains of cannabis they consume.

Cultivation 52

Cultivation Marijuana Environment Patients 52

CannaMD

AUGUST 19, 2020

Unlike THC, CBD has a high margin of safety and is well tolerated pharmacologically even after treatments of up to 1500 mg/day for two weeks in both animals and humans, which suggests its feasibility to reduce SARS-CoV2 induced lung inflammation/pathology and disease severity. .” Note: Study extracts were applied via media.

Research and Development 141

Research and Development Marijuana Extraction Terpenes 141

Cannabis Law Report

NOVEMBER 24, 2021

However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. This article analyses media representations of medicinal cannabis in Australian medical publications. Background.

Research and Development 52

Research and Development Medicine Access Media 52

The Blunt Truth

MAY 26, 2020

In his statement, Commissioner Hahn noted that the FDA was working on: 1) continuing to educate the public on the risks of CBD; 2) seeking reliable data on the safety and benefits of CBD, including opening the public docket on the matter; and 3) monitoring the marketplace for the sale and marketing of unapproved drugs.

CBD 103

CBD Hemp Programs Food 103

Cannabis Law Report

FEBRUARY 28, 2022

Show More According to the Drug Enforcement Administration (DEA), Schedule I drugs have “no currently accepted medical use in the United States, a lack of accepted safety for use under medical supervision, and a high potential for abuse.” Mitchell et al., Divito & Robert F. 11 × 11. Psychiatry May Never Be the Same , N.Y. TIMES (Nov.

Research and Development 52

Research and Development Therapy Law Clinical Trials 52

Cannabis Law Report

APRIL 8, 2022

This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. MAPS completed the first Phase 1 safety study with MDMA and resumed working on a protocol for anxiety associated with cancer.

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52